Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 4
Submit an article Journal homepage
134
Views
25
CrossRef citations to date
0
Altmetric
Review

Future directions in the treatment of Alzheimer’s disease

Roger Bullock Kingshill Research Centre, Victoria Hospital, Swindon, SN1 4HZ, UK. [email protected]
Pages 303-314 | Published online: 02 Mar 2005

  • DOODY RS, STEVENS JC, BECK C et al.: Practice parameter: management of dementia (an evidence-based review). Neurology (2001) 56:1154–1166.
  • REISBERG B, DOODY R, STOFFER A et al.: Memantine in moderate-to-severe Alzheimer's disease. N Engl.' Med. (2003) 348:1333–1341.
  • HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353–356.
  • OHM TG, GLOCKNER F, DISTL R et al.: Plasticity and the spread of Alzheimer's disease-like changes. Neurochem. Res. (2003) 28:1715–23.
  • KNOPMAN DS, PARISI JE, SAL VIATI A et al.: Neuropathology of cognitively normal elderly. Neuropathol Exp. Neurol (2003) 62(11):1087–1095.
  • McLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of AP amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neural. (1999) 46:860–866
  • KOISTINAHO M, ORT M, CIMADEVILLA JM et al.: Specific spatial learning deficits become severe with age in 3-amyloid precursor protein transgenic mice that harbor diffuse 3-amyloid deposits but do not form plaques. Proc. Nati Acad. Sci. USA (2001) 98:14675–14680.
  • SHAW KT, UTSUKI T, ROGERS J et al: Phenserine regulates translation of 3-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA (2001) 98:7605–7610.
  • ••Paper on the mode-of-action of phenserine, which is currently in advanced development and is potentially the next compound to be launched.
  • ROGERS JT, RANDALL JD, EDER PS: Alzheimer's disease drug discovery targeted to the APP mRNA 5 "untranslated region. J. MM. Neurosci. (2002) 19:77–82.
  • SISODIA SS, ST GEORGE-HYSLOP PH: y-Secretase, Notch, AP and Alzheimer's disease: where do the presenilins fit in? Nat. Rev Neurosci. (2002) 3:281–290.
  • HARDY J: Alzheimer's disease: genetic evidence points to a single pathogenesis. Ann. Neurol (2003) 54:143–144.
  • •Paper of interest.
  • TAKASUGI N, TOMITA T, HAYASHI I et al.: The role of presenilin cofactors in the gamma-secretase complex. Nature (2003) 422:438–441.
  • GOLDE TE, YOUNKIN SG: Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends MM. Med. (2001) 6:264–269.
  • ESLER WP, WOLFE MS: A portrait of alzheimer secretases - new features and familiar faces. Science (2001) 293:1449–1454.
  • NI CY, MURPHY MP, GOLDE TE et al: y-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294:2179–2181.
  • PETIT A, BIHEL F, ALVES DA COSTA C et al.: New protease inhibitors prevent y-secretase-mediated production of A340/ 42 without affecting Notch cleavage. Nat. Cell. Biol. (2001) 3:507–511.
  • •Paper of interest.
  • WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the y-secretase inhibitor LY-411,575 inhibits Abeta production and alters lymphopoiesis and intestinal cell differentiation. Biol. Chem. (2004) (Epub ahead of print).
  • GOLDE TE: Alzheimer's disease therapy: can the amyloid cascade be halted?' Clin. Invest. (2003) 111:11–18.
  • ERIKSEN JL, SAGI SA, SMITH TE et al: NSAIDs and enantiomers of flurbiprofen target y-secretase and lower Al342 in vivo. Clin. Invest. (2003) 112:440–449.
  • ••Observational evidence suggests thatNSAIDs have a protective effect in AD, but clinical studies have been inconclusive. This paper suggests that some NSAIDs have properties, other than being anti-inflammatory, that confer this effect making them likely candidates for study.
  • ROBERDS SL, ANDERSON J, BASI G et al.: BACE knockout mice are healthy despite lacking the primary I3-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. MM. Genet. (2001) 10:1317–1324.
  • LUO Y, BOLON B, KAHN S et al.: Mice deficient in BACE1, the Alzheimer's I3-secretase, have normal phenotype and abolished 3-amyloid generation. Nat. Neurosci. (2001) 4:231–232.
  • HONG L, KOELSCH G, LIN X et al.: Structure of the protease domain of memapsin 2 (I3-secretase) complexed with inhibitor. Science (2000) 290:150–153.
  • •Paper of interest.
  • SCHOLEFIELD Z, YATES EA, WAYNE G: Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's I3-secretase. Biol. (2003) 163:97–107.
  • GANDY S: Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol. Aging (2002) 23:1009–1016.
  • GANDY S, ALMEIDA OP, FONTE J et al.: Chemical andropause and amyloid-3 peptide. JAMA (2001) 285:2195–2196
  • MULNARD RA, COTMAN CW, KAWAS C et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA (2000) 283:1007–1015.
  • WANG PN, LIAO SQ, LUI RS et al.: Effects of estrogen on cognition, mood and cerebral blood flow in Alzheimer's disease: a controlled study. Neurology (2000) 54:2061–2066.
  • RAPP SR, ESPELAND MA, SHUMAKER SA: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 289:2663–2672.
  • ANTHONY JC, BREITNER JC, ZANDI PP: Reduced prevalence of ad in users of NSAIDS and h2 receptor antagonists: the cache county study. Neurology (2000) 54:2066–2071.
  • BROE GA, GRAYSON DA, CREASEY HM et al: Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch. Neurol. (2000) 57:1586–1591.
  • JARVIK GP, WIJSMAN EM, KUKULL WA et al.: Interactions of apolipoprotein E genotype, total cholesterol level, age and sex in prediction of Alzheimer's disease: a case-control study. Neurology (1995) 45:1092–1096.
  • DARTIGUES JF, LETENNEUR L: Genetic epidemiology of Alzheimer's disease. Curr: Opin. Neurol. (2000) 13:385–389.
  • HOLTZMAN DM: Apolipoprotein isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of
  • •• Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2000) 97:2892–2897.
  • SPARKS DL, SCHEFF SW, HUNSAKER JC et al.: Induction of Alzheimer-like 13-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. (1994) 126:88–94.
  • •Paper of interest.
  • KOJRO E: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the I3-secretase ADAM 10. Proc. Natl. Acad. Sci. USA (2001) 98:5815–5820.
  • FASSBENDER K: Simvastatin strongly reduces levels of Alzheimer's disease 13-amyloid peptides AP 42 and AP 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:5856–5861.
  • GOLDE TE, ECKMAN CB: Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov. Today(2001) 20:1049–1055.
  • JICK H: Statins and the risk of dementia.Lancet (2000) 356:1627–1631.
  • SHEPHERD J, BLAUW G, MURPHY M et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet (2002) 360:1623–1630.
  • SIMONS M, SCHWARZLER F, LUTJOHANN D et al.: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. (2002) 52:346–350.
  • BORRONI B, PETTANATI C, BORDOLONALI T et al.: Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer's disease. Neurosci. Lett. (2003) 343:213–215.
  • TAYLOR DL, DIEMEL LT, POCOCK JM: Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity.f Neurosci. (2003) 23:2150–60.
  • SOTO C: Protein misfolding and disease;protein refolding and therapy. FEBS Lett. (2001) 498:204–207.
  • PERMANNE B, ADESSI C, SABORIO GP et al.: Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a I3-sheet breaker peptide. FASEB (2002) 16:860–862.
  • •Paper of interest.
  • GERVAIS F, PAQUETTE J, MORISETTE C et al.: A low molecular weight GAG mimetic compound reduces brain amyloid burden in hAPP transgenic mice. Proceedings 7th International Geneva/ Springfield Symposium on Advances in Alzheimer Therapy Geneva, Switzerland (2002).
  • PERMANNE B, ADESSI C, SABORIO GP et al: Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a 13-sheet breaker peptide. FASEBJ (2002) 16:860–862.
  • MIURA T, SUZUKI K, KOHATA N, TAKEUCHI H: Metal binding modes of Alzheimer's amyloid 13-peptide in insoluble aggregates and soluble complexes. Biochemistry (2000) 39:7024–7031.
  • ••Comprehensive review of how metal ionsplay a potential role in the neurodegenerative processes in AD.
  • BUSH Al: The metallobiology of Alzheimer's disease. Trends Neurosci. (2003) 26:207–214.
  • CHERNY RA, ATWOOD CS, XILINAS ME et al.: Treatment with a copper-zinc chelator markedly and rapidly inhibits 13-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 30:665–676.
  • •Paper of interest.
  • RITCHIE CW, BUSH Al, MacKINNON A et al.: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A13 amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. (2003) 60:1685–1691.
  • AGDEPPA ED, KEPE V, LIU J et al: 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol. Imaging Biol. (2003) 5:404–417.
  • AKIYAMA H, BARGER S, BARNUM S et al.: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21:383–421.
  • McGEER PL, SCHULZER M, McGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425–432.
  • IN T VELD BA, RUITENBERG A, HOFMAN et al.: Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl. I Med. (2001) 345:1515–1521.
  • TABET N, FELDMAN H: Indomethacin for treatment of AD Patients. Cochrane Database Syst. Rev (2002) (2):CD003673.
  • VAN GOOL WA, WEINSTEIN HC, SCHELTENS P et al.: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 358:455–460.
  • SAINATI SM, INGRAM DM, TAL WALKER S et al.: Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden (2000).
  • BLOCK G, NORMAN B, LIU G et al.: Aclinical trial of rofecoxib, a selective COX-2 inhibitor, for the treatment of Alzheimer's disease. Neurobioi Agftig (2002) 23:S73–S74.
  • AISEN P, DAVIS KL, BERG JD et al.: Arandomized controlled trial of prednisone in Alzheimer's disease. Neurology (2000) 54:588–593.
  • AISEN PS, SCHAFER K, GRUNDMAN M et al.: Effects of rofecoxib or naproxen vs. placebo on Alzheimer's disease progression. JAMA (2003) 289:2819–2826.
  • REINES SA, BLOCK GA, MORRIS JC et al.: Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 62:66–71.
  • •Paper of interest.
  • HO L, PUROHIT D, HAROUTUNIAN V et al.: Neuronal cyclooxygenase-2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer's disease. Arch. Neurol. (2001) 58:487–492.
  • XIANG Z, HO L, YEMUL S et al: COX-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr: (2002) 10:271–278.
  • LIM GP, YANG F, CHU T et al.: Ibuprofensuppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Neurosci. (2000) 20:5709–5714.
  • HALLIDAY GM, SHEPHERD CE, MCCANN H et al.: Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neural. (2000) 57:831–836.
  • •Paper of interest.
  • VVEGGEN S, ERIKSEN JL, DAS Pet al.: A subset of NSAIDs lower amyloidogenic AB 42 independently of cyclooxygenase activity. Nature (2001) 414:212-216pp.
  • PATERSON D, NORDBERG A: Neuronal nicotinic receptors in the human brain. Frog. Neurobiol. (2000) 6:75–111.
  • SAHAKIAN BJ, JONES GMM: The effects of nicotine on attention, information processing, and working memory in patients with dementia of the alzheimer type. In: Effects of Nicotine on Biological Systems. F Adlkofer, K Thruau (Eds), Birkhauser, Basel, Switzerland (1991).
  • •Paper of interest.
  • MAELICKE A, SAMOCHOCKI M, JOSTOCK R et al.: Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry (2001) 49:279–288.
  • ARROYO G, ALDEA M, FUENTEALBA J, GARCIA AG: Nicotinic receptor, galantamine and Alzheimer's disease. Rev Neural. (2002) 34:1057–1065.
  • CAPSONI S, GIANNOTTA S, CATTANEO A: Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Nati Acad. Sci. USA. (2002) 99:12432–12437.
  • ARIAS E, ALES E, GABILAN NH et al.: Galantamine prevents apoptosis induced by P-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology (2004) 46:103–114.
  • WILCOCK GW, TRUYEN L, LILIENFELD S, MAHABLESHWARKAR AR: Long term cognitive effects of galantamine in the treatment of mild to moderate Alzheimer's disease: evidence from 48 months of treatment. American Psychiatric Association 156th Annual Meeting, San Francisco, USA (2003) (Poster).
  • KRISHNAN KR, CHARLES HC, DORAISWAMY PM et al.: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. Psychiatry. (2003) 160:2003–2011.
  • WINBLAD B, ENGEDAL K, SOININEN H et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology(2001) 57:489–954.
  • FELDMAN H, GAUTHIER S, HECKER J et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology(2001) 57:613–620.
  • SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-P attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
  • JANUS C, PEARSON J, McLAURIN J et al.: A 3-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2002) 408:979–982.
  • MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A 3-peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
  • •Paper of interest.
  • ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after A342 immunization. Neurology(2003) 61(1):46–54.
  • HOCK C, KONIETZKO U, PAPASSOTIROPOULOS A et al.: Generation of antibodies specific for P-amyloid by vaccination of patients with Alzheimer's disease. Nat. Med. (2002) 11:1270–1275.
  • ••This is the first post mortem of a patientwho was given the arnyloid immunisation and showed a reduction in the expected number of plaques in a similar manner to that seen in the mice experiments.
  • NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-P peptide: a case report. Nat. Med. (2003) 9:448–452.
  • HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against P-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547–554.
  • PFEIFER M, BONCRISTIANO S, BONDOLFI L: Cerebral hemorrhage after passive antiAP immunotherapy. Science (2002) 298:1379.
  • McLAURIN J, CE CAL R, KIERSTEAD ME: Therapeutically effective antibodies against amyloid-P peptide target amyloid-P residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 11:1263–1269.
  • SIGURDSSON E M, SCHOLTZOVA H, MEHTA P D et al.: Immunization with a nontoxic/nonfibrillar amyloid-p homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. Pathol. (2001) 159:439–447.
  • FRENKEL D, SOLOMON B: Towards Alzheimer's P-amyloid vaccination. Biologicals (2001) 29:243–247.
  • BACSKAI BJ, KAJDASZ ST, CHRISTIE RH et al.: Imaging of amyloid-P deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369–372.
  • •Paper of interest.
  • IWATA N, TSUBUKI S, TAKAKI Y et al.: Metabolic regulation of brain Ap by neprilysin. Science (2001) 292:1550–1552.
  • ••This shows how an endogenous enzymethat degrades arnyloid, functions less well with age, offering a putative causal mechanism for arnyloid deposition and the opportunity for treatment.
  • APELT J, ACH K, SCHLIEBS R: Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of P-amyloid plaques. Neurosci. Lett. (2003) 339:183–186.
  • MARR RA, ROCKENSTEIN E, MUKHERJEE A et al.: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. (2003) 23:1992–1996
  • GROSSMAN H: Does diabetes protect orprovoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr. (2003) 8:815–823.
  • MILLER BC, ECKMAN EA, SAMBAMURTI K et al.: Amyloid-P peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Nati Acad. Sci. USA (2003) 100:6221–6226.
  • •Paper of interest.
  • COOK DG, LEVERENZ JB, McMILLAN PJ et al.: Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon 4 allele. Am. J. Pathol (2003) 162:313–319.
  • RENSINK AA, OTTE-HOLLER I, DE BOER R et al: Insulin inhibits amyloid 13-induced cell death in cultured human brain pericytes. Neurobiol Aging (2004) 25:93–103.
  • SONG ES, JULIANO MA, JULIANO L et al.: Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. (2003) 278:49789–49794.
  • GILMAN CP, PERRY T, FURUKAWA K et al.: Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. I Neurochem. (2003) 87:1137–1144.
  • PERRY T, LAHIRI DK, SAMBAMURTI K et al.: Glucagon-like peptide-1 decreases endogenous amyloid-I3 peptide (A13) levels and protects hippocampal neurons from death induced by Abeta and iron.' Neurosci. Res. (2003) 72:603–612.
  • PEPYS MB, HERBERT J, HUTCHINSON WL et al.: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 417:254–259.
  • MOE CHARS D, DEWACHTER I, LORENT K et al: Early phenotypic changes in transgenic mice that over express different mutants of amyloid precursor protein in brain. Biol. Chem. (1999) 274:6483–6492.
  • ••Paper describing a mouse model that offerssuggestions as to the mechanism of how tangles follow plaques.
  • ODDO S, CACCAMO A, KITAZAWA M et al.: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging. (2003) 24:1063–1070.
  • GONG CX, LIU F, WU G et al.: Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. j. Neurochem. (2004) 88:298–310.
  • MIZUTANI T: Familial parkinsonism and dementia with ballooned neurons, agyrophilic neuronal inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles and Lewy bodies. Rinsho Shinkeigaku (1999) 39:1262–1263.
  • RAPOPORT M, DAWSON HN, BINDER LI, VITEK MP, FERREIRA A: Tau is essential to 13-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA (2002) 99:6364–6369.
  • LEWIS J, DICKSON DW, LIN WL et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science (2001) 293:1487–1491.
  • GOTZ J, CHEN F, VAN DORPE J, NITSCH RIVI: Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Ab 42 fibrils. Science (2001) 293:1491–1495.
  • •Paper of interest.
  • RYDER J, SU Y, LIU F et al: Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. (2003) 312:922–929.
  • LOVESTONE S, DAVIS DR, WEBSTER MT et al.: lithium reduces tau phosphorylation - effects in living cells and in neurones at therapeutic concentrations. Biol. Psychiatry (1999) 45:995–1003.
  • VAN WAUVVE J, HAEFNER B: Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug News Perspect (2003) 16:557–565.
  • GUO Q: Cyclin-dependent kinase 5 - a neuronal killer? Sci. Aging Knowledge Environ. (2003) 2003(50):pe36.
  • MESULAM MM: Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron (1999) 24:521–529.
  • SEILER M, SCHWAB ME: Specific retrograde transport of nerve growth factor (NGF) from cortex to nucleus basalis in the rat. Brain Res. (1984) 300:33–39.
  • ERIKSDOTTER-JOHNAGEN M, NORDBERG A, AMBERLA K et al: Intra-cerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Ceriatr. Cogn. Disord (1998) 9:246–257.
  • KUBO T, NISHIMURA S, MURASUGI T et al.: 6-Ethyl-N,N'-bis(3- hydroxypheny0 [1,3,5]triazine-2,4-diamine (RS-0466) enhances the protective effect of brain-derived neurotrophic factor on amyloid 13-induced cytotoxicity in cortical neurones. Pharmacol Toxicol. (2003) 93:264–268.
  • GRUNDMAN M, CAPPARELLI E, KIM HT et al.: A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. (2003) 73:539–553.
  • VON BERNHARDI R, RAMIREZ G, DE FERRARI GV, INESTROSA NC: Acetylcholinesterase induces the expression of the beta-amyloid precursor protein in glia and activates glial cells in culture. Neurobiol Dis. (2003) 14:447–457.
  • •Paper of interest.
  • RIEDERER P, DANIELCZYK W, GRUNBLATT E: Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology (2004) 25:271–277.
  • RUETHER E, HUSMANN R, KINZLER E et al.: A 28-week, double-blind, placebo-controlled study with cerebrolysin in patients with mild to moderate Alzheimer's disease. Int. Clin. Psychopharmacol. (2001) 16:253–263.
  • DOGGRELL SA: The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin. Investig. Drugs. (2004) 13:69–72.
  • •Paper of interest.
  • WILMS H, CLAASEN J, ROHL C et al.: Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis. (2003) 14:417–424.
  • CARDOSO SM, OLIVEIRA CR: Inhibition of NF-icB renders cells more vulnerable to apoptosis induced by amyloid-I3 peptides. Free Radic. Res. (2003) 37:967–973.
  • ••Stem cell research report of anotherneurodegenerative disease gives hope that the methodology may transfer to AD.
  • PLUCHINO S, QUATTRINI A, BRAMBILLA E: Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 422:688–694.
  • •Paper of interest.
  • RICE CM, HALFPENNY CA, SCOLDING NJ: Stem cells for the treatment of neurological disease. Transfus. Med. (2003) 13:351–361.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.